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Abstract 
Although cardiac myofibrillar ATPase activity has been shown to be depressed uring the development of diabetic heart dysfunction, 
the mechanisms of this alteration are not fully understood. Since phosphorylation ftroponin I (TnI) is known to decrease the myofibrillar 
ATPase activity, the present study was undertaken to examine the TnI phosphorylation capacity in the diabetic heart homogenate. For this 
purpose rats were made diabetic by injecting streptozotocin (65 mg/kg; i.v.) and the hearts were removed 8wk later. Some 6 wk diabetic 
animals were injected with insulin (3 U/day) for 2 wk. TnI content in the heart homogenate was measured by immunoblot assay, the 
mRNA abundance for TnI gene was determined by Northern blot analysis and the in vitro phosphorylation level of TnI was estimated by 
the ratio of phosphorylated TnI and total (phosphorylated and unphosphorylated) TnI. No significant changes in TnI content and gene 
expression of TnI were observed in right and left ventricles from the diabetic rats. However, the phosphorylation of TnI was higher 
(~ 40%) in the diabetic hearts; this change was reversible upon insulin treatment. These results regarding TnI phosphorylation measured 
under in vitro conditions uggest hat increased phosphorylation of TnI may contribute toward the depression in cardiac myofibrillar 
ATPase activity in chronic diabetes. 
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1. Introduction 
Chronic diabetes mellitus has been reported to exhibit 
heart dysfunction [1-5]. Previous studies have shown that 
cardiac contractile proteins in the diabetic heart are altered 
with respect o myofibrillar ATPase, actomyosin ATPase 
and myosin ATPase activities as well as myosin isozyme 
composition [1,6-9]. Although changes in myosin isozyme 
composition can be seen to explain myofibrillar ATPase 
activity and subsequent contractile dysfunction in diabetic 
heart, very little is known about the status of regulatory 
proteins such as troponin (Tn) and tropomyosin (Tm) 
during the development of diabetic cardiomyopathy. In
particular, it should be noted that cardiac Tn is a complex 
protein having 3 subunits, namely CaZ+-binding TnC, the 
tropomyosin-binding TnT and the ATPase-inhibiting TnI. 
Furthermore, TnI is phosphorylated by a variety of protein 
kinases [10-12]. The data obtained from earlier investiga- 
tions have identified that the phosphorylation of TnI by 
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protein kinase C results in a decrease of the actomyosin 
ATPase activity [13-15] and a decrease in the actin-myosin 
interaction [14]. Furthermore, phosphorylation of TnI by 
protein kinase A has been associated with a reduced 
sensitivity of the myofibrillar Mg2+-ATPase to Ca 2 ÷ [16]. 
Accordingly, it is hypothesized that an increase in TnI 
phosphorylation or TnI content in the diabetic heart may 
directly or indirectly contribute towards the depressed 
cardiac myofibrillar ATPase activity in chronic diabetes. 
The present study was therefore undertaken to investigate 
the amount of TnI, the mRNA abundance for TnI gene and 
the level of TnI phosphorylation i  the heart homogenate 
from control and diabetic rats. In addition, this study 
examined whether these alterations are reversible upon 
treatment of diabetic rats with insulin. 
2. Materials and methods 
2.1. Experimental model 
Male Sprague-Dawley rats weighing approx. 200 g 
were randomly separated into control and experimental 
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groups. The experimental nimals received an intravenous 
injection of 0.1 M citrate-buffered streptozotocin (pH 4.5) 
at a dosage of 65 mg/kg body wt. Control animals 
received a similar injection of the vehicle alone. These 
animals were maintained for 8 wk on normal rat chow and 
water ad libitum, and then killed by decapitation. In some 
experiments, at 6 wk after streptozotocin jection, ran- 
domly selected iabetic animals were given 3 U protamine 
zinc insulin/day for 2 wk (subcutaneous injection) and 
were labelled as the insulin-treated group. After removing 
the heart, atria and large vessels were carefully trimmed, 
and the left and right ventricles were separated, weighed 
and frozen at -72°C for the experiment. Blood samples 
were analyzed for glucose and insulin levels by using the 
Worthington Statzyme Reagent Kit and standard radioim- 
munoassay techniques (Amersham), respectively. Some of 
the animals were used for the isolation of ventricular (both 
ventricles) myofibrils and determination of myofibrillar 
Mg 2÷ ATPase and CaZ+-stimulated ATPase activities ac- 
cording to the procedures used earlier [6,9]. The experi- 
mental model employed in this study is similar to that used 
previously for establishing the presence of diabetic car- 
diomyopathy as indicated by alterations in cardiac func- 
tion, metabolism, and ultrastructure [1,2,4,6,17,18]. 
2.2. Preparation of  cardiac muscle homogenate 
Homogenates were prepared from pieces (30-40 mg) of 
both left and right ventricles from control, diabetic and 
insulin-treated rats [19,20]. The muscle was homogenized 
by Brinkmann homogenizer with Kinematica 87/Polytron 
PTA 7K1 for 3-5 s in the homogenizing buffer (100 ~1 
buffer per 2 mg of muscle) containing 60 mM KC1, 1 mM 
cysteine, 20 mM imidazole (pH 6.9), 1 mM MgC12, 1 mM 
oubain, 10 mM NaN 3, l mM CaC12, 0.01% leupeptin, 250 
/zM phenylmethylsulfonylfluoride an  1 mM dithiothreitol 
(DTT). The homogenization procedure was carried out at 
4°C and samples were placed on a rotator and mixed for at 
least 15 min to allow the suspensions to warm up to room 
temperature b fore use in subsequent assays [20]. 
2.3. Analysis of  troponin I content 
TnI relative contents in the control, experimental nd 
insulin-treated cardiac muscle homogenates were obtained 
by running 12% mini sodium dodecyl sulfate polyacryl- 
amide gel electrophoresis (SDS-PAGE). The concentration 
of protein in the homogenate was adjusted to 1 mg/ml 
with the homogenizing buffer and the SDS-PAGE loading 
buffer was added into the homogenizing buffer (1 part 
loading buffer to 3 parts homogenate). The SDS-PAGE 
loading buffer contained 0.25 M Tris-HCl (pH 6.8), 8% 
(w/v)  sodium dodecyl sulfate (SDS), 45% glycerol, 20% 
/3-mercaptoethanol, and 0.006% bromophenol blue. The 
protein loads for control, experimental, and insulin-treated 
groups were the same (7.5 /zg in each well). The elec- 
trophoresis was carried out at 200 V for 40-45 min. The 
gels were stained with Coomassie brilliant blue or the 
proteins in homogenate separated by SDS-PAGE were 
electroblotted to lmmobilon-P transfer membrane (Milli- 
pore Company) in a transfer buffer which contained 25 
mM Tris-HC1, 120 mM glycine and 20% methanol (v/v)  
for the determination of relative contents with immoblot- 
ting analysis. 
The transferred membrane was shaken for 2 h in block- 
ing buffer, which contained TBS (10 mM Tris-HC1, 150 
mM NaCI) and 5% fat-free powdered milk, then incubated 
for 1 or 2 h at room temperature with monoclonal anti-TnI 
antibodies (1:10000; a kind gift from Dr. Stefano Schi- 
affino, University of Padova, Italy). The transferred mem- 
branes were subsequently incubated with biotinylated 
anti-mouse IgG (1:1000; Amersham) for 40 min and then 
finally with strepdavidin conjugated horseradish peroxi- 
dase (1:5000; Amersham) for 40 min. The blots were 
rinsed in the TBS-T (10 mM Tris-HC1, 150 mM NaC1 and 
0.2% Tween 20) 3 times (5 min each time) between each 
of the preceding steps. For chemiluminescent detection, 
the membrane sheets were dipped into luminal substrate 
solution (Amersham) and the chemilumigrams were devel- 
oped on Hyperfilm-ECL (Amersham) to visualize TnI. The 
normal exposure times ranged from 30 s to 5 min. The 
relative content of TnI was determined by the model 
GS-670 Imaging Densitometer (Bio-Rad Company) with 
the Image Analysis Software Version 1.0. 
2.4. RNA isolation and Northern blot analysis 
Total myocardial RNA was isolated from left and fight 
ventricles of control, experimental nd insulin-treated rat 
by the method of Chomczynski and Sacchi [21] at 8 wk 
after induction of diabetes. Briefly, the flesh tissue was 
washed twice with a solution containing 10 mM 3-(N-mor- 
pholino)propanesulfonic acid (MOPS) and 10 mM sodium 
ethylenediaminetetraacetate (EDTA) and frozen at - 196°C 
in liquid nitrogen. The frozen samples were then ground 
with mortar and pestle while immersed in liquid nitrogen. 
Powdered samples were suspended in solution D (4 M 
guanidine isothiocyanate, 25 mM sodium citrate (pH 7.0), 
0.5% N-lauroylsarcosine and 0.1 M 2-mercaptoethanol) 
and subjected to polytron homogenization. Tissue ho- 
mogenates were treated with 0.1 volume of 2 M sodium 
acetate (pH 4.0), equal volume of water-saturated phenol 
and 0.2 volumes of chloroform-isoamyl alcohol mixture 
(49:1) and mixed by inversion. The mixture was cooled on 
ice for an additional 15 min and was centrifuged at 6000 x 
g for 20 min at 4°C. The RNA-containing aqueous phase 
was transferred to fresh tube, mixed with an equal volume 
of isopropranol and kept at -20°C for 60 min. RNA was 
sedimented at 10000 X g for 20 min and resuspended in
solution D. Re-precipitation of RNA by isopropranol was 
carried out at -20°C for 1 h and the RNA pellets were 
suspended in 75% ethanol (molecular biology grade di- 
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luted with DEPC-treated water). After sedimentation, RNA 
pellets were washed a second time in ethanol and vacuum 
dried. Samples were dissolved in DEPC-treated water and 
the concentration of nucleonic acid calculated from the 
absorbance at 260 and 280 nm prior to size fraction. 
Steady-state l vel of TnI mRNA was determined by North- 
ern hybridization analysis; 20 ~g of total RNA was dena- 
tured in 50% formamide, 7% formaldehyde, 20 mM mor- 
pholinopropane-sulphonic acid (MOPS) pH 7.4, 2 mM 
EDTA (pH 8.0), 0.1% sodium dodecyl sulfate (SDS) and 
was subjected to electrophoresis in a 1.2% 
agarose/formaidehyde gel to size fractionate the mRNA 
transcripts. The fractionated RNA was transferred 
(capillary) to a 0.45 mm positive charge-modified nylon 
filter (Zeta-Probe membrane, Bio-Rad). After 24 hr, the 
filter was removed and nucleic acids were covalently 
crosslinked to the matrix using UV radiation (UV 
Stratalinker 2400, Stratagene). Each membrane was hy- 
bridized with 32p-labeled cDNA probes at 43°C. TnI and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
cDNA probes were labeled by random primer DNA label- 
ing system using Klenow fragment [22,23]. Filters were 
exposed to x-ray film (Kodak X-OMAT) at -80°C with 
intensifying screens. Results of autoradiographs from 
Northern blot analysis were quantified by densitometry 
(Bio-Rad imaging densitometer GS 670). The signal of TnI 
mRNA was normalized to that of GAPDH mRNA to 
account for differences in loading and/or transfer. It should 
be pointed out that the signal for GAPDH mRNA in 
diabetic heart did not change when normalized with re- 
spect to that for 18S or 28S signals. 
2.5. Troponin I phosphorylation 
The level of TnI phosphorylation was estimated by 
monitoring the ratio of phosphorylated and total (phospho- 
rylated plus unphosphorylated) TnI [24-26]. Tissue ho- 
mogenate (10 mg per assay tube) was equilibrated for 10 
min at 30°C prior to initiating the assay procedures. In 
order to obtain maximum reaction of TnI phosphorylation, 
all samples were incubated at 30°C for 10 min in the 
presence of 1 mM MgE+-ATP and 1 mM CaC12. The 
reaction in the sample was stopped by adding ice cold 10% 
(w/v)  trichloroacetic acid (TCA). The TCA precipitated 
homogenate was centrifuged at 15 000 × g for 30 min and 
then the pellet was resuspended in acetone containing l0 
mM dithiothreitol (DTT) and placed on a rotator for l h at 
room temperature. These samples were centrifuged and the 
pellets were solubilized in 400 /xl of the buffer (6.4 M 
urea, 17 mM Tris-HCl, 19.5 mM glycine (pH 8.6), 10 mM 
DTT, l0 mM EGTA, 1 mM EDTA, 5 mM NaF, 1 mM 
phenylmethylsulfonylfluoride and 0.04% bromophenol b ue 
in final concentration) by resuspending and placing the 
tubes on a rotator for at least 2 h. These samples were 
centrifuged (15 000 × g) for 30 min and then immediately 
loaded onto native polyacrylamide gels. Phosphorylated 
TnI and unphosphorylated TnI were separated by non-de- 
naturing 10% polyacrylamide electrophoresis [26]. All gels 
were subjected to pre-electrophoresis for 1.5 h at 400 V; 
the running tank buffer contained 20 mM Tris-HC1, 22 
mM glycine, 1 mM sodium thioglycate and 1 mM DTT. 
Samples (40 /xl) were applied to each well and subjected 
to electrophoresis u ing 350 V for 19 to 21 h at 4°C (runs 
were stopped within 1 to 2 h after the bromophenol blue 
tracking dye exited the gel). Separated proteins were then 
electroblotted to nitrocellulose sheets by employing a 25 
mM Na2HPO 4 transfer buffer at a current of 1.5 amps and 
temperature of 15°C for 1 h. After transfer, the bands of 
phosphorylated and unphosphorylated TnI on nitrocellu- 
lose sheets were detected by ECL-Western blot analysis 
with anti-TnI antibody. The imaging densitometer was 
employed to scan the developed films and to quantify the 
TnI phosphorylation. It should be mentioned that the iden- 
tity of phosphorylated TnI was established by adding 
staurosporine, an inhibitor of both protein kinase C and 
protein kinase A [27], at a concentration of 10 ng/ml  
before the addition of Mg2+-ATP and CaCI 2 in some 
assay tubes. No effort was made to characterize whether 
TnI phosphorylation, asmeasured in this study, was due to 
protein kinase A and/or protein kinase C. 
2.6. Data analysis 
Data are expressed as mean _+ SE. Unpaired Student's 
t-test was employed when comparing the relative content 
Table 1 
Genera] characteristics of control, diabetic and insulin-treated animals 
Control Diabetic Diabetic + Insulin 
body wt. (g) 556 + 23 309 _+ 18 * 362 + 26 * 
ventficular wt. (mg) 1079 + 97 848 + 38 * 1020 + 28 
ventricular/body wt. (mg/g) 2.27 + 0.04 2.75 +_ 0.006 * 2.40 + 0.064 
plasma glucose (mg/dl) 159 +9 498 +_ 5 * 192 + 7 
plasma insulin (/zU/ml) 29 + 2.9 12 + 0.9 * 34 -t- 1.2 
myofibrillar Mg2+-ATPase 206 + 11 152 + 8 * 188 + 10 
act. (nmol Pi/mg per 5 min) 
myofibrillar Ca2+-stimulated 884 + 26 572 _+ 31 * 856 ± 30 
ATPase act. (nmol Pi/mg per 5 rain) 
Values are mean + SE of 6 experiments. * Significantly different from control (P < 0.05). 
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of TnI, mRNA signal for TnI and the specific TnI 
phosphorylation data points in control, diabetic and in- 
sulin-treated samples. P < 0.05 was taken to represent a
significant difference. 
3. Results 
3. l. General characteristics of diabetic and insulin-treated 
animals 
Compared to the control, the body as well as ventricular 
growth were significantly retarded and the ratio of ventric- 
ular to body weight, was increased in rats 8 wk after 
streptozotocin jection (Table 1). In diabetic animals, the 
plasma glucose concentration was markedly increased and 
the plasma insulin level was depressed when compared to 
control animals. Daily injection of insulin to the diabetic 
animals for 2 wk normalized plasma glucose and insulin 
concentrations as well as the ventricular weight and ratio 
of ventricular to body weight; however, the insulin-treated 
diabetic rats still had lower body weight. These character- 
istics are similar to those reported for diabetic animals 
from this laboratory and by others [2,4,6,17,18,28]. De- 
pressed myofibrillar ATPase activity in diabetic heart in 
comparison to the control values and reversal of this 
change upon treating the diabetic animals with insulin are 
also in agreement with our previous observations [6,9]. 
3.2. Analysis of troponin I content 
The TnI in the cardiac muscle homogenate from con- 
trol, experimental, and insulin-treated rats was identified 
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Fig. 2. Quantification f TnI in the cardiac muscle homogenate with 
immunoblot analysis. A typical immunoblot in the figure and the analysis 
of results reveal that no significant change in the relative contents of Tnl 
in left and right ventricles from diabetic and insulin-treated rats in 
comparison tothe control value (n = 6 for each group). 
by ECL Western blot. Fig. ! shows a band which appears 
to represent the TnI with a molecular weight of about 29 
kDa. Fig. 2 shows a typical ECL Western blot with 
monoclonal anti-TnI and a densitometer analysis, which 
demonstrated there was no appreciable difference in the 
relative TnI content (expressed as percentage of the control 
value) of myocardium from control, diabetic, and insulin- 
treated rats. 
3.3. Analysis of troponin I mRNA expression 
A B C 
66kD 
36kD 
29kD 
20kD 
14kD 
TnI 
Fig. 1. Identification ftroponin I in rat cardiac muscle. Troponin I band 
is shown on the 10% mini SDS-PAGE gel stained with Brilliant 
Coomassie Blue as well as by ECL Western blotting assay. A: Rat 
cardiac muscle (Brilliant Coomassie Blue); B: High molecular weight 
marker (Brilliant Comassie Blue); C: Rat cardiac muscle (ECL Western 
blouing). Tnl: Troponin I.
The mRNA abundance of TnI was determined by 
Northern blot analysis. The nLRNA abundance of TnI was 
expressed as percentage of the control value in 
Tn I /GAPDH ratio. No significant change was found in 
the diabetic cardiac muscles when compared with the ratio 
of control or insulin-treated groups (Fig. 3). 
3.4. Phosphorylation of troponin I
In order to establish the identity of phosphorylated TnI, 
the phosphorylation reaction was carried out in the absence 
and presence of 10 ng /ml  staurosporine, an inhibitor of 
both protein kinase C and protein kinase A [27]. The 
immunoblots in Fig. 4a show that the phosphorylated TnI 
(lower band) was markedly decreased in the presence of 
staurosporine (lane A) in comparison to the homogenate 
without staurosporine (lane B). Accordingly, the level of 
TnI phosphorylation was estimated by the ratio of 
phosphorylated (lower band) total TnI (both phospho- 
rylated and unphosphorylated lower and upper bands, re- 
spectively). Fig. 4b shows the immunoblots of unphospho- 
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Fig. 3. Determination of mRNA abundance forthe TnI gene by Northern 
blot analysis. A typical Northern Blot of TnI mRNA from left and right 
ventricles of the control, diabetic and insulin-treated rat is shown on the 
top of each bar. There was no significant change in the TnI/GAPDH 
ratio in the diabetic and insulin-treated groups compared with the ratio of 
control in comparison to the control value (n = 6 to 8 for each group). 
rylated (upper bands) and phosphorylated (lower bands) 
Tnl in heart homogenates from control, diabetic and in- 
sulin-treated animals. Fig. 5 shows the results of TnI 
phosphorylation i all three groups. The phosphorylation 
of TnI in the diabetic ardiac muscle was increased by 40 
to 50% in comparison to the control value. After the 
treatment of diabetic animals for 2 wk with insulin, the 
increased phosphorylation f TnI in both the left and right 
ventricles declined by 20 to 30% in comparison to the 
diabetic group. 
4. D iscuss ion  
The presence of cardiac dysfunction including signifi- 
cant depressions in contractile force generation and relax- 
ation as well as cardiac pump insufficiently has been 
reported in clinical and experimental conditions of diabetes 
[1,29,30]. Because myofibrillar ATPase activity is closely 
related to the contractile force development in the heart, 
cardiac dysfunction in chronic diabetes was suggested to 
be associated with depressed myofibrillar ATPase activity. 
Indeed, previous studies have reported that there was a 
significant depression in ATPase activities of cardiac con- 
tractile protein preparations from diabetic animals [1,7-9]. 
Although several investigators have suggested that the 
depressed myofibrillar ATPase activity in diabetic heart 
may be due to changes in the composition of myosin 
isozymes [7,8,31], the contribution of changes in regula- 
TnI 
A 
TnI-p 
B C D E F 
TnI 
TnI-p 
Fig. 4. Western blot analysis of unphosphorylated an phosphorylated 
TnI of cardiac muscles, a.Unphosphorylated (upper bands) and phospho- 
rylated (lower bands) TnI of the same cardiac muscle homogenate with 
(A) and without (B) staurosporine (10 ng/ml), an inhibitor of both 
protein kinase C and protein kinase A. The phosphorylation level of TnI 
was markedly decreased in the homogenate with staurosporine, b. Changes 
in TnI phosphorylation n the diabetic ardiac muscle homogenate in 
comparison to the control and insulin-treated group. TnI: Unphospho- 
rylated troponin I. TnI-p: Phosphorylated roponin I. A and B: Left and 
right ventricles from control animals. C and D: Left and right ventricles 
from diabetic animals. E and F: Left and right ventricles from insulin- 
treated animals. 
0 
100 
['--7 Control 
1 Diabetic 
Diabetic+Insulin 
LV RV 
Fig. 5. Troponin I phosphorylation n the left and right ventricles from 
control, diabetic and insulin-treated rats. The phosphorylation of Tnl in 
the diabetic ardiac muscle markedly increased by 40-50% in compari- 
son to the value of control and this increased phosphorylation of TnI 
declined by the 20-30% in comparison to the diabetic group after the 2 
wk of treatment with insulin (n = 6 for each group). 
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tory proteins such as Tn and Tm in explaining the dia- 
betes-induced alterations in myofibrillar ATPase and car- 
diac dysfunction cannot be overlooked. Recent studies 
involving SDS-PAGE and Western blot analysis of the 
regulatory proteins have revealed major changes in the 
TnT band in the diabetic myocardium [32]. It should be 
noted that Tn and Tm are required for the contraction of 
cardiac muscle and are known to prevent crossbridge 
cycling between myosin and actin through blocking of 
myosin binding sites on actin in the absence of Ca 2+ [33]. 
In addition, these regulatory proteins have been shown to 
inhibit a kinetic step in the actomyosin ATP hydrolysis 
such as release of phosphate or release of ADP from the 
actin-myosin complex [34-37]. For the contractile appara- 
tus to become 'activated' in the presence of Ca 2+, a 
conformational change in the structure of TnC upon the 
binding Ca 2+ results in an increased affinity of TnC for 
the ATPase inhibitory region of TnI and functional detach- 
ment of TnI from actin [38-40]. Furthermore this process 
allows Tm to roll toward the center of the actin helical 
groove, uncovering myosin binding sites and ultimately 
leading to actomyosin ATPase activation and muscle con- 
traction [11,41]. Therefore, TnI is considered to play an 
important regulatory role in the interaction between actin 
and myosin and any change in the TnI can be seen to alter 
the actomyosin ATPase activities. 
In the present study we have observed no appreciable 
difference in the protein and mRNA levels of TnI between 
streptozotocin-induced diabetic and control cardiac mus- 
cles. On the other hand, the level of TnI phosphorylation, 
as measured under in vitro conditions, was increased in 
both left and right ventricles from the diabetic animals in 
comparison to the control value. Although both protein 
kinase C and protein kinase A are known to increase TnI 
phosphorylation [ 13-16], the in vitro data presented in the 
study do not permit any conclusion whether the observed 
increase in TnI phosphorylation in the diabetic heart is due 
to alterations in the protein kinase C and/or protein kinase 
A activities. Since the depression in myofibrillar Ca 2+- 
stimulated ATPase activity in diabetic heart was not asso- 
ciated with any change in the sensitivity of myofibrils to 
Ca 2+ [9], it is possible that the increased TnI phosphoryla- 
tion observed in this study may predominantly be due to 
some changes in the protein kinase C activity. This view is 
based upon the observations that protein kinase C depen- 
dent TnI phosphorylation was associated with a depression 
of Ca 2 +-stimulated ATPase activity without any change in 
the sensitivity of myofibrils to Ca 2+ [13-15] whereas 
protein kinase A mediated TnI phosphorylation resulted in 
a decrease in Ca 2+ sensitivity without any change in the 
maximal activity of myofibrillar ATPase [15,16]. Thus 
further studies by employing specific inhibitors of TnI 
phosphorylation u der both in vitro and in vivo conditions 
are required to elucidate the exact mechanisms of in- 
creased TnI phosphorylation in diabetic heart. 
The inhibitory effect of TnI phosphorylation myofib- 
rillar ATPase in diabetic heart can be explained on the 
basis of a partial detachment of phosphorylated TnI from 
actin-Tm in the presence of Ca 2 +, perhaps due to enhanced 
ionic and allosteric interactions [15] and reduced release of 
phosphate and ADP from the actin-myosin complex [14]. 
Furthermore, treatment of diabetic animals with insulin, 
which has been reported to reverse the depressed myofib- 
rillar ATPase activities [6,9], was also observed to reverse 
the increased level of TnI phosphorylation in the diabetic 
heart. Therefore it appears that an increase in TnI phospho- 
rylation may represent one of the mechanisms associated 
with depressed myofibrillar ATPase activity in diabetic 
heart. Since the inhibition of the actomyosin Mg 2 +-ATPase 
activity can result in decreased cardiac contractility due to 
a reduction in the rate of contraction and the rate of force 
development [42], the depression in myofibrillar Ca 2+- 
stimulated Mg 2 +-ATPase by the increased phosphorylation 
of TnI may contribute to contractile dysfunction i diabetic 
heart. Although our experiments concerning changes in 
plasma glucose and insulin levels in streptozotocin-in- 
jected animals with or without insulin treatment indicate 
that the observed increase in cardiac TnI phosphorylation 
may be a consequence of metabolic stress, the exact 
metabolic signal leading to changes in regulatory proteins 
including TnI phosphorylation remains to be unclear at 
present. 
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